Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Donislecel-jujn
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes
Details : Lantidra (donislecel-jujn suspension for hepatic portal vein infusion) is an allogeneic pancreatic islet cellular therapy y indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c.
Brand Name : Lantidra
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 29, 2023
Lead Product(s) : Donislecel-jujn
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?